Physician profile
Sanda A Tan
NPI 1043422421
$6,671.14
in general payments reported to CMS, 2019-2025
32 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2021: $58.89 · 2022: $509 · 2023: $408 · 2024: $4,361 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,176 · Food and Beverage: $2,521 · Long Term Medical Supply Or Device Loan: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,176.04 |
| Food and Beverage | $2,521.38 |
| Long Term Medical Supply Or Device Loan | $146.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,469.83 | 2019-2025 | Da Vinci Surgical System |
| Stryker Corporation | $636.97 | 2023-2024 | 1788, Inspace |
| Medtronic, INC. | $474.96 | 2021-2025 | Interstim, Ligasure |
| Integra Lifesciences Corporation | $294.76 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Boston Scientific Corporation | $166.02 | 2025 | Axonics |
| Tela Bio, INC. | $157.47 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Axonics, INC. | $149.73 | 2024 | Axonics |
| Dilon Technologies, INC. | $110.88 | 2025 | Hemoblast Bellows |
| Acera Surgical, INC. | $110.18 | 2025 | Restrata Wound Matrix |
| Ethicon US, LLC | $109.21 | 2024 | Echelon Flex, Endopath, Echelon Circular |
| Davol INC. | $105.73 | 2023-2024 | Phasix Mesh |
| Acell, INC. | $101.60 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $100.93 | 2025 | |
| Coopersurgical, INC. | $92.64 | 2022 | |
| Thd America, INC. | $85.73 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $68.59 | 2025 | |
| Zimvie INC. | $47.40 | 2022-2023 | |
| Si-Bone, INC. | $46.07 | 2021-2024 | |
| Cochlear Americas | $38.17 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Teleflex LLC | $37.55 | 2025 | Titan Sgs Bailout Chuck |
| Kci USA, INC. | $33.65 | 2021-2022 | |
| Kerecis Limited | $30.78 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Conmed Corporation | $28.77 | 2024 | Airseal |
| Regeneron Healthcare Solutions, INC. | $28.53 | 2023 | Libtayo |
| Abbott Laboratories | $27.24 | 2022 | |
| Radius Health, INC. | $17.67 | 2023 | Tymlos |
| Genzyme Corporation | $17.44 | 2022 | |
| Heraeus Medical, LLC. | $17.39 | 2022 | |
| Vericel Corporation | $17.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.02 | 2023 | Gattex |
| Novartis Pharmaceuticals Corporation | $15.87 | 2022 | |
| Orthofix Medical, INC. | $15.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanda Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.